Related Experiment Videos
[Chemotherapy in metastasizing prostate carcinoma]
D Heimbach1, M Wirth, H Frohmüller
1Urologische Klinik und Poliklinik, Universität Würzburg.
Der Urologe. Ausg. A
|September 1, 1991
Summary
Combination chemotherapy showed limited efficacy in advanced prostate cancer, but effectively palliated pain in most patients. Further research is needed for improved treatment outcomes.
Area of Science:
- Urology
- Medical Oncology
Background:
- Metastatic hormone-resistant prostate cancer presents a significant clinical challenge.
- Limited effective treatment options exist for advanced stages of prostate cancer.
Purpose of the Study:
- To evaluate the efficacy of combination chemotherapy in patients with metastatic hormone-resistant prostate cancer.
- To assess the palliative effects of chemotherapy on tumor pain in this patient cohort.
Main Methods:
- Retrospective analysis of 17 patients with metastatic hormone-resistant prostate cancer treated with combination chemotherapy.
- Data collection on treatment response (complete remission, partial remission, stable disease, progression) and pain palliation.
Main Results:
- One patient achieved complete remission (4 months).
- Three patients experienced partial remission; five had stable disease (average 6.8 months).
- Tumor progression observed in 7 patients; significant pain palliation achieved in 16 evaluable cases.
Conclusions:
- Combination chemotherapy offers limited tumor response in metastatic hormone-resistant prostate cancer.
- Chemotherapy demonstrates a valuable role in palliating tumor pain for these patients.
- The study highlights the need for novel therapeutic strategies for advanced prostate cancer.